PRESS-RELEASE filed Sep 10, 2026 at 06:04 ET
Teva priced a ~$4.9B multi-tranche senior notes offering across five maturities (2032-2037), with proceeds to fund the conditional redemption of up to ~$4.5B in higher-coupon debt (6.750% 2028s, 7.875% 2029s, 7.375% 2029s, plus portions of 4.750% 2027s and 4.375% 2030s). This liability management refinancing reduces near-term interest costs and extends maturities, a credit-positive move for bondholders but neutral for equity holders as it does not alter the fundamental business outlook or leverage trajectory beyond the refinancing math. The cross-filing 424B5 from 2 days ago previewed this offering; the pricing confirmation removes uncertainty on size and coupon rates, with settlement expected September 16, 2026.